In the meantime, we have been offering our unique position and networks in South Africa to give assistance to the Japanese company to assist with their own efforts in the markets of Sub Saharan Africa. This is currently the only revenue we have. With our efforts as detailed above, we do however hope to be commercially active in the sales of pharmaceuticals by quarter 4 of 2017.
We have already initiated discussions with various companies to register and supply our products in Nigeria and Kenya, and once supply starts will be able to leverage the volumes to supply many other African countries. This will generate much needed export revenue for South Africa.